The President & CEO of CryoPort (NASDAQ: CYRX) is Buying Shares

By Carrie Williams

Yesterday, the President & CEO of CryoPort (CYRXResearch Report), Jerrell Shelton, bought shares of CYRX for $46.98K.

Following Jerrell Shelton’s last CYRX Buy transaction on March 12, 2019, the stock climbed by 3.4%. This recent transaction increases Jerrell Shelton’s holding in the company by 1.07% to a total of $4.74 million.

See today’s analyst top recommended stocks >>

Based on CryoPort’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $9.58 million and GAAP net loss of $12.47 million. In comparison, last year the company earned revenue of $5.29 million and had a GAAP net loss of $2.14 million. The company has a one-year high of $25.02 and a one-year low of $8.28. Currently, CryoPort has an average volume of 380.27K.

Starting in December 2018, CYRX received 17 Buy ratings in a row.

Jerrell Shelton’s trades have generated a 19.5% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Irvine, CA.